An idea that has actually been doing the rounds on social networks recommends that particular heart and kidney medications make individuals more susceptible to COVID-19 A brand-new commentary strongly contests this.
The commentary cautions that terminating these high blood pressure and kidney medications would seriously endanger the health of those taking the drugs for high blood pressure, heart disease, and chronic kidney illness.
A. H. Jan Danser, from the Department of Internal Medication at the Erasmus Medical Centre in Rotterdam, The Netherlands, is the first author of the commentary, which appears in High Blood Pressure, a journal of the American Heart Association (AHA).
Stay informed with live updates on the current COVID-19 break out and visit our coronavirus hub for more guidance on prevention and treatment.
Danser co-authored the paper with Dr. Murray Epstein, from the Department of Nephrology and Hypertension at the University of Miami Miller School of Medicine in Florida, and Daniel Fight, from the Division of Nephrology/Hypertension at the Northwestern University Feinberg School of Medicine in Chicago.
As Danser and colleagues describe in their paper, the idea that some heart and kidney medications may raise the threat of issues and death from a SARS-CoV-2 infection arose when it became known that the “angiotensin-converting enzyme 2” (ACE2) receptor assists in the entry of the virus into healthy cells.
Specifically, some researchers that Danser and associates quote have actually suggested that taking the renin-angiotensin system (RAS) blockers– particularly, angiotensin II type 1 receptor blockers (ARBs)– might raise the risk of developing an extreme and potentially fatal form of COVID-19
RAS blockers are drugs doctors use to deal with high blood pressure. ARBs also treat high blood pressure, congestive heart failure, and kidney illness, among other conditions.
In their